- TraderTV Research
- Posts
- Trader TV Watchlist - October 2, 2025
Trader TV Watchlist - October 2, 2025
Thursday October 2, 2025
Welcome to the TraderTV Live Morning Research Note. Here's what's making major moves in the market today.
TraderTV.LIVE™ features a daily live trading broadcast, professional education and an active community of more than 450,000 subscribers. Join us on YouTube every weekday from 8:30am to 4:30pm EST for the first and only professional trading show on YouTube Live!
Economic Events:
1030 - Fed’s Logan speaks
Premarket Trading:
Trading Higher ($): AMD, TSLA, NBIS
Trading Lower ($): INTC, UFG, GOOGL
Earnings Today:
Premarket: ANGO
In The News
Tesla Inc (TSLA)
+1.66%
On watch ahead of its Q3 2025 delivery numbers, expected to be released on the morning of Thursday, October 2. On average, analysts are expecting Tesla to have delivered 447,000 vehicles during the quarter; this would mark a decrease from 463,000 deliveries in Q3 2024. CEO Elon Musk became the first person in the world to have a net worth of $500 billion as of Wednesday afternoon, according to Forbes’ Real-Time Billionaires tracker.
Intel Corp (INTC)
-0.81%
On Wednesday afternoon, Semafor reported that the company is in early talks to add AMD as a foundry customer; details and the likelihood of a deal remain uncertain. Winning AMD’s business would be a significant boost for Intel’s foundry push, as it seeks to catch up with TSMC and has recently gained backing from the White House, Nvidia, and Softbank.
Occidental Petroleum Corp (OXY)
+1.61%
Trading higher premarket after Berkshire Hathaway announced a $9.7 billion cash deal to purchase OxyChem, the company’s petrochemical unit. This is Berkshire Hathaway’s largest deal since its $11.6 billion purchase of Alleghany in 2022. Occidental also announced the promotion of Richard Jackson to Senior VP and COO.
Apple Inc (AAPL)
+0.47%
Bloomberg reported that the company has paused its Vision Pro headset overhaul to focus on developing smart glasses that could rival Meta’s offerings, after the $3,499 device struggled with limited content and cheaper competition. The company is working on two models: an iPhone-linked version without a display targeted for 2027, and a display-equipped version planned for 2028; efforts are underway to speed up the development of the display-equipped model. Additionally, Morgan Stanley raised its price target on Apple to $298 from $240, citing stronger-than-expected demand for the upcoming iPhone 17 cycle.
Taiwan Semiconductor Manufacturing Co Ltd (TSM)
+1.56%
On watch after Taiwan rejected Washington’s proposal to split U.S. semiconductor supply 50-50 by manufacturing half of the chips locally, with Vice Premier Cheng Li-chiun saying the idea wasn’t even discussed in recent trade talks. Instead, Taiwan focused on lowering tariffs and securing exemptions. US officials, including Commerce Secretary Howard Lutnick, continue to push for greater onshoring of chip production to reduce reliance on Taiwan.
Nebius Group NV (NBIS)
+4.80%
Bloomberg reported that Microsoft has secured access to over 100,000 of Nvidia’s GB300 chips through its previously-announced deal withNebius. This access was designed to boost Microsoft’s AI development while easing data center constraints. The move is part of more than $33 billion in commitments to neocloud providers like CoreWeave, Nscale, and Lambda, reflecting Microsoft’s aggressive push to secure computing capacity in the AI race.
Crypto Stocks
+1.32%
Trading higher as a group in tandem with Ethereum and Bitcoin, which are trading marginally higher this morning following strong performances on Wednesday. Citi raised its price targets for Bitcoin to $132K by year-end and $181K in 12 months, and for Ethereum to $4.5K by year-end and $5.4K in 12 months. These price targets were attributed to ETF inflows and institutional demand. The bank views Bitcoin as “digital gold” with clearer momentum, while Ethereum’s trajectory is less certain given its more complex use cases.
MSTR, MARA, IBIT, ETHE, COIN, HUT, CLSK, RIOT, BLSH, CRCL, GEMI
Opendoor Technologies Inc (OPEN)
+1.88%
Trading higher premarket after receiving preliminary court approval for a settlement in the derivative case Gera v. Palihapitiya, covering related litigation in Delaware, The approval, initially issued on September 11, followed a global mediation and agreement on corporate governance reforms. Opendoor closed marginally higher on Wednesday after co-founder and director Eric Hu and US Representative Cleo Fields both disclosed purchases of the company’s shares.
Meta Platforms Inc (META)
+0.69%
Oppenheimer weighed in on the stock amid reports that Apple is working on a product to compete with its smart glasses offerings. The analyst said that Meta’s new Ray-Ban Display smart glasses face the same hurdles that doomed Google Glass, including eye strain and blurry vision. These features, according to Oppenheimer, make the glasses unsuitable as everyday wearables like the Apple Watch.
Alphabet Inc (GOOGL)
-0.03%
Jefferies raised its price target on the stock to $285 from $230 with a Buy rating, highlighting Google’s potential to transform search into a leading AI-driven “decision engine.” The firm cited Gemini’s unified interface, AI overviews, Circle to Search, and Lens as key tools that could strengthen Google’s dominance from discovery to purchase. Morgan Stanley also raised its price target on the stock from $210 to $270.
Robinhood Markets Inc (HOOD)
+1.47%
CEO Vlad Tenev discussed the impact of tokenization at the TOKEN2049 crypto event. Tenev said tokenization of real-world assets like stocks and real estate is inevitable and will transform global financial markets within the next five years, though full adoption could take over a decade. He noted Europe is likely to lead adoption, while the U.S. may lag due to entrenched financial infrastructure. Robinhood was added to the S&P 500 in mid-September and is the strongest year-to-date performer in the index.
Aspire Biopharma Holdings Inc (ASBP)
+75.63%
Gapping up after announcing a milestone roadmap for its sublingual aspirin on Wednesday morning. The schedule targets FDA submission of the treatment by H2 2025. The company also outlined key 2026 milestones for its needle-free semaglutide medication. Aspire Biopharma has a market capitalization of $10.63 million.